研究单位：[1]Tasly Pharmaceuticals,Inc.[2]The First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine Guangzhou,Guangdong,China[4]Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China[5]The First Affiliated Hospital of hunan Medical University Changsha,Hunan,China[6]Jiangsu Province Hospital of Integrated Traditional Chinese and Western Medicine Nanjing,Jiangsu,China[7]Affiliated Hospital of Shandong University of Traditional Chinese Medicine Jinan,Shandong,China[8]The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine Tianjin,Tianjin,China[9]The First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[10]Yunnan Province Hospital of Traditional Chinese Medicine Kunming,Yunnan,China
研究目的：
This study is to investigate the efficacy and safety of Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis (SpA) patients and to explore the optimal dosage.
